21Mar/13

NICE rejects Novartis' Afinitor, but OKs GSK's Revolade, InterMune's Esbriet – PharmaTimes

NICE rejects Novartis’ Afinitor, but OKs GSK’s Revolade, InterMune’s Esbriet
PharmaTimes
According to Novartis, Afinitor (everolimus) is the first new licensed therapeutic approach in fifteen years offering substantial impact on hormone responsive advanced breast cancer, which affects over 30,000 women in the UK. The gold standard of care
Positive NICE news for GSK’s Revolade and InterMune’s EsbrietThe Pharma Letter

all 6 news articles »

21Mar/13

How the shiny “agate” stones in jewelry and rosary beads are killing workers – GlobalPost


GlobalPost

How the shiny “agate” stones in jewelry and rosary beads are killing workers
GlobalPost
KHAMBHAT, India — A few years ago, when occupational safety activists came to Hydersha Diwan’s village here, 300 miles north of Mumbai, he drove them away with threats and bluster. Today, he wishes that he’d listened. Doctors say the 50-year-old is
How the shiny ‘agate’ stones in jewelry and rosary beads are killing workersDaily Democrat

all 2 news articles »

21Mar/13

Breakthrough breast cancer drug 'too expensive' – Telegraph.co.uk


Telegraph.co.uk

Breakthrough breast cancer drug ‘too expensive’
Telegraph.co.uk
At that stage, chemotherapy is usually the only option. Last September early trial results were published showing that when combined with chemo, everolimus could more than double the time tumours were ‘stalled’, compared to chemo alone. The respective
Breast cancer drug does not provide value for money, regulator rulesThe Guardian
UK cost body rejects Novartis breast cancer drugReuters UK

all 13 news articles »